Johnson & Johnson-backed Galapagos, already listed in Amsterdam and Brussels, has filed for an initial public offering in the US.
Belgium-based, corporate-backed biotechnology company Galapagos, which is already listed on Euronext Brussels and Euronext Amsterdam, has filed for a $150m initial public offering on Nasdaq.
Galapagos’ shareholders include pharmaceutical company Johnson & Johnson (which currently holds a 7.6% stake), financial services conglomerate Capital Group (5%), and Van Herk Investments, the venture capital unit of residential, retail and commercial real estate company Van Herk Groep (5.1%).
Galapagos is developing treatments for cystic fibrosis, a genetic disorder affecting the lungs…
